Resources/
Phil Blog
Phil Blog
How to Streamline Pharmaceutical Commercialization
Developing a new drug is an incredibly costly, time-consuming, and high-risk venture. In the 21st century, it typically takes ten years and over $2.6 billion for a pharmaceutical manufacturer to move a drug from its initial discovery into the marketplace. While getting an innovative treatment approved for patient use is a major milestone, it’s just the beginning and certainly does not ensure the brand’s commercial success
Optimizing your Drug Distribution Model
The primary objective of a drug distribution model is to ensure patients receive the medications they need when they need them. A manufacturer’s strategy for getting their product from manufacturer to patient – effectively and efficiently – is crucial to the success of a therapy. The complexity of the distribution process has been exacerbated as a result of the pandemic
Determining the Optimal Channel Strategy for Your Pharma Brand
In this on-demand webinar, Patrick Leary, Phil’s Chief Commercial Officer, discusses challenges pharmaceutical brands are facing and how a well-thought-out channel strategy is essential to these key success factors: - Speed-to-therapy - Payer Coverage (Approvals of Rx) - Pull-through to First Fill - Adherence to Therapy - Reimbursement A fragmented commercialization strategy poses significant risks to brand growth and threatens things like the patient and prescriber experience, rates of prescription coverage and pull through, medication adherence, and ultimately, profit margins and commercial success. In this webinar, you’ll learn some of the market factors impacting channel strategy, such as payer cost control measures, out-of-pocket costs, and patient consumerization, along with seven important channel strategy considerations and eight components of channel partner evaluation. You will also see a case study on one brand’s successful launch where they exceeded their commercial and access targets with: A 95% enrollment rate 50% of Trx covered in the first month 3x average adherence vs other channels 4x + net sales vs other channels
Technology Trends Shaping the Future of the Pharmaceutical Commercialization
Due to its highly regulated, high-risk environment, the pharmaceutical industry has traditionally been slow to adopt new technologies. A conservative approach to technology implementation means that pharma companies may be missing out on the advantages digital technologies offer and have lagged behind other industries in creating rich customer experiences; however, the Covid-19 pandemic significantly accelerated digital transformation throughout the industry. The latest healthcare technologies promise to transform the development and delivery of innovative pharmaceutical therapies and elevate the experience for patients and providers
Migraine - Post Approval Insights
Migraine is a neurological disorder that affects approximately 1 in 6 Americans and leads to over 1 million emergency department visits in the US annually. Just like many neurological conditions, the treatment landscape of triptans, opioids and NSAIDs has fallen short of providing a sustainable solution for migraine patients with drugs that have subpar efficacy and intolerable side-effects. The condition has been difficult to study and characterize due to varying levels of severity, causes and symptoms and traditional therapies have not specifically addressed the disease pathology of migraines
Ready to learn more?
Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance.
